Evidence map›Paper›PMID 42766279›Full record

ReviewAmerican journal of clinical dermatology2026

Laser Therapy for Cutaneous Vascular Anomalies: Efficacy, Safety, and Innovations.

Mustufa Jafry, C William Hanke

Abstract readReview
PubMed Publisher
In one paragraph

Review in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mustufa JafryLaser and Skin Surgery Center of Indiana, Indianapolis, IN, USA. mj0192@hotmail.com.ORCID http://orcid.org/0009-0002-5521-018X
C William HankeLaser and Skin Surgery Center of Indiana, Indianapolis, IN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous vascular anomalies comprise a heterogeneous spectrum of congenital or early-onset vascular lesions, including capillary, venous, lymphatic, and arteriovenous malformations, as well as selected vascular tumors such as infantile hemangiomas. Aberrant vascular development frequently produces conspicuous lesions with attendant psychosocial, cosmetic, and sometimes functional burden. Over the past several decades, laser- and light-based interventions have become fundamental to management, with progressive refinements yielding notable gains in both efficacy and safety. This narrative review evaluates the clinical performance, safety profile, and recent technological advances of laser therapies for cutaneous vascular anomalies, with particular attention to pulsed dye laser (PDL), neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers, intense pulsed light (IPL), and selected emerging platforms including potassium titanyl phosphate (KTP) lasers and multimodal strategies. Relevant literature was reviewed with emphasis on efficacy by lesion subtype, patient selection, peri-procedural planning, post-treatment care, and complication mitigation. PDL remains the reference modality for many superficial vascular lesions, including port-wine stains and superficial infantile hemangiomas, whereas Nd:YAG lasers offer superior penetration for deeper or bulkier lesions at the cost of greater discomfort and a narrower safety margin. IPL and KTP devices provide additional versatility, particularly for superficial telangiectatic and erythematous lesions. Emerging strategies-including dual-wavelength regimens, next-generation large-spot devices, and adjunctive approaches for treatment-resistant lesions-continue to expand the therapeutic armamentarium. When tailored to lesion morphology, skin phototype, patient age, and anatomic site, laser therapy remains a safe and effective cornerstone in the management of cutaneous vascular anomalies. Ongoing innovation and more personalized treatment algorithms are expected to further improve durability of clearance, reduce recurrence, and refine long-term outcomes.

Identifiers

PMID42766279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.